Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement
Rapport Therapeutics (RAPP) closed public offerings of 9.76M shares of common stock at $21.00 per share, $172.5M in convertible notes, and a concurrent private placement of 1.43M shares. Total net proceeds are approximately $410.7M. Proceeds will fund clinical trials, R&D, and general corporate purposes. The notes have a 2.25% interest rate and mature in 2032.
How this was made
The 30-second read
Why it matters
The capital raise strengthens the balance sheet through 2029, enabling continued trial funding while increasing share supply.
Market read
First‑report of a $410 M biotech financing; material for traders monitoring cash‑flow events.
What to watch
Potential future in‑license or acquisition opportunities funded by the proceeds could unlock upside not reflected in the immediate price.
Background
Rapport Therapeutics is a clinical‑stage biotech focused on neurological and psychiatric disorders, previously announced the offerings.
Ticker impact
Rapport Therapeutics disclosed the closing of a $410.7 million public offering of common stock, pre‑funded warrants and convertible notes, a first‑report primary capital‑raise.
mixed pressure as market prices in dilution offset by new capital for RAPP's pipeline
The size of the raise ($410 M) is material and new; investors will weigh dilution against funding of RAP‑219 trials.
Market effects
Biotech sector may see modest uplift as a peer secures sizable financing for clinical development.
U.S. biotech market gains a new cash‑rich player, but no broader regional effect.
Limited to investors tracking small‑cap biotech financing; no global macro impact.
Counterpoint
The dilution could outweigh the benefit of new cash, pressuring the stock lower in the near term.
Key entities
- underwriterMorgan Stanley
Joint book‑running manager for the offerings.
- underwriterLeerink Partners
Joint book‑running manager for the offerings.
- underwriterEvercore ISI
Joint book‑running manager for the offerings.
